Similarly, atorvastatin attenuated diabetes-associated renal injury by reducing Nox4-induced ROS production and RhoA activity and by normalizing Akt/glycogen synthase kinase 3 beta (GSK3β) signaling pathways, which are known to be important players in renal pathology [97]. This evidence concerns the gene GSK3B and diabetes mellitus.